JPH0414644B2 - - Google Patents
Info
- Publication number
- JPH0414644B2 JPH0414644B2 JP59028414A JP2841484A JPH0414644B2 JP H0414644 B2 JPH0414644 B2 JP H0414644B2 JP 59028414 A JP59028414 A JP 59028414A JP 2841484 A JP2841484 A JP 2841484A JP H0414644 B2 JPH0414644 B2 JP H0414644B2
- Authority
- JP
- Japan
- Prior art keywords
- nitrate
- glyceryl
- gtn
- composition
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HXWLJBVVXXBZCM-UHFFFAOYSA-N 2,3-dihydroxypropyl nitrate Chemical compound OCC(O)CO[N+]([O-])=O HXWLJBVVXXBZCM-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 18
- QYZBMMOLPVKAPU-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl nitrate Chemical compound OCC(CO)O[N+]([O-])=O QYZBMMOLPVKAPU-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000001990 intravenous administration Methods 0.000 claims abstract description 12
- 208000002815 pulmonary hypertension Diseases 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 10
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 30
- 229960003711 glyceryl trinitrate Drugs 0.000 description 30
- 241000700159 Rattus Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 241000282472 Canis lupus familiaris Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 239000003826 tablet Substances 0.000 description 11
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 8
- 102000002852 Vasopressins Human genes 0.000 description 8
- 108010004977 Vasopressins Proteins 0.000 description 8
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 229960003726 vasopressin Drugs 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000001077 hypotensive effect Effects 0.000 description 5
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 5
- 229960000201 isosorbide dinitrate Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 206010003225 Arteriospasm coronary Diseases 0.000 description 4
- 208000003890 Coronary Vasospasm Diseases 0.000 description 4
- 239000000006 Nitroglycerin Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 201000011634 coronary artery vasospasm Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 230000003257 anti-anginal effect Effects 0.000 description 3
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 3
- 229960004704 dihydroergotamine Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 229940098466 sublingual tablet Drugs 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000020128 Mitral stenosis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 208000012929 large congenital melanocytic nevus Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C203/00—Esters of nitric or nitrous acid
- C07C203/02—Esters of nitric acid
- C07C203/04—Esters of nitric acid having nitrate groups bound to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Storage Of Web-Like Or Filamentary Materials (AREA)
- Beans For Foods Or Fodder (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3305690.0 | 1983-02-18 | ||
| DE19833305690 DE3305690A1 (de) | 1983-02-18 | 1983-02-18 | Glycerinmononitrate zur behandlung der angina pectoris |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59210016A JPS59210016A (ja) | 1984-11-28 |
| JPH0414644B2 true JPH0414644B2 (en:Method) | 1992-03-13 |
Family
ID=6191227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59028414A Granted JPS59210016A (ja) | 1983-02-18 | 1984-02-17 | グリセリルモノニトレ−ト組成物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0116944B1 (en:Method) |
| JP (1) | JPS59210016A (en:Method) |
| AT (1) | ATE21483T1 (en:Method) |
| DE (2) | DE3305690A1 (en:Method) |
| DK (1) | DK74184A (en:Method) |
| IL (1) | IL70990A0 (en:Method) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879308A (en) * | 1987-08-11 | 1989-11-07 | Lyphomed, Inc. | Aqueous nitroglycerin injection and manufacturing process |
| US5001151A (en) * | 1987-08-11 | 1991-03-19 | Fujisawa Usa, Inc. | Aqueous nitroglycerin injection and manufacturing process |
| JPH0645538B2 (ja) * | 1987-09-30 | 1994-06-15 | 日本化薬株式会社 | ニトログリセリンスプレー剤 |
| NL8802276A (nl) * | 1988-09-15 | 1990-04-02 | Cedona Pharm Bv | Geneesmiddel met relaxerende werking, dat als aktieve stof een nitraatester bevat. |
| US5278192A (en) * | 1992-07-02 | 1994-01-11 | The Research Foundation Of State University Of New York | Method of vasodilator therapy for treating a patient with a condition |
-
1983
- 1983-02-18 DE DE19833305690 patent/DE3305690A1/de not_active Withdrawn
-
1984
- 1984-02-15 AT AT84101527T patent/ATE21483T1/de not_active IP Right Cessation
- 1984-02-15 EP EP84101527A patent/EP0116944B1/de not_active Expired
- 1984-02-15 DE DE8484101527T patent/DE3460493D1/de not_active Expired
- 1984-02-17 IL IL70990A patent/IL70990A0/xx unknown
- 1984-02-17 JP JP59028414A patent/JPS59210016A/ja active Granted
- 1984-02-17 DK DK74184A patent/DK74184A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59210016A (ja) | 1984-11-28 |
| ATE21483T1 (de) | 1986-09-15 |
| IL70990A0 (en) | 1984-05-31 |
| DK74184D0 (da) | 1984-02-17 |
| DK74184A (da) | 1984-08-19 |
| DE3460493D1 (en) | 1986-09-25 |
| EP0116944B1 (de) | 1986-08-20 |
| DE3305690A1 (de) | 1984-08-30 |
| EP0116944A1 (de) | 1984-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2328283C2 (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
| KAYDEN et al. | Procaine amide: a review | |
| KR20100134032A (ko) | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 | |
| HU199302B (en) | Process for producing synergic pharmaceutical compositions having hypotensive activity | |
| EP0287341B1 (en) | Rectally absorbable form of l-dopa | |
| CA1217428A (en) | Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same | |
| US6083991A (en) | Anti-arrhythmic composition and methods of treatment | |
| US3519717A (en) | Novel method for lowering high blood pressure and compositions therefor | |
| JPH0414644B2 (en:Method) | ||
| JPS625913A (ja) | ジヒドロピリジン含有製剤 | |
| Hill et al. | Effects of bepridil on exercise tolerance in chronic stable angina: a double-blind, randomized, placebo-controlled, crossover trial | |
| JPS61183225A (ja) | ９，１０‐ジヒドロ麦角アルカロイド含有医薬組成物 | |
| AU639722B2 (en) | Use of arylalkylamides in the treatment of neurodegenerative diseases | |
| EP0413694B1 (fr) | Preparations medicamenteuses cardio-protectrices comprenant l'amiodarone, un derive nitre, notamment le dinitrate d'isosorbide et facultativement un beta-bloqueur | |
| JPS61155327A (ja) | ジヒドロピリジン化合物を含有する抗動脈硬化剤 | |
| FR2544614A1 (fr) | Nouvelle association medicamenteuse pour le traitement de l'hypertension | |
| US3961073A (en) | Antidepressant | |
| US3914425A (en) | Antitussive codeine composition | |
| JPH01216923A (ja) | プロスタグランジン類の選択的作用増強剤 | |
| JPS60208914A (ja) | 肝障害の予防、治療剤 | |
| RU2007169C1 (ru) | Средство, обладающее антигипертензивным действием | |
| JPS6245525A (ja) | 脂質低下剤 | |
| JPS6058726B2 (ja) | プリン誘導体を有効成分として含有する抗アレルギ−，鎮痛，鎮静剤 | |
| JPS59193884A (ja) | １，４−ジヒドロピリジン誘導体 | |
| US3469005A (en) | Method and composition for reducing blood pressure in mammals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |